Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases

Background and Aims Alcohol abuse and nonalcoholic fatty liver disease (NAFLD) are common causes of liver disease. Diabetes mellitus (DM) is a common comorbidity among NAFLD patients. We performed this study with the specific aim to examine the impact of DM on progression of alcoholic liver disease (ALD) liver and NAFLD. Methods Medical charts of 480 patients with ALD or NAFLD (2004–2011) managed at a tertiary center were retrospectively reviewed. NAFLD was diagnosed based on exclusion of other causes of liver disease and alcohol use of <10 g/d. ALD was diagnosed based on alcohol use of >40 g/d in women or >60 g/d in men for >5 years. Results Of 480 patients (307 NAFLD), 200 diabetics differed from nondiabetics for: age (52±11 vs. 49±11 years; p=0.004); male gender (48% vs. 57%; p=0.03); metabolic syndrome (49% vs. 30%; p=0.0002); NAFLD (80% vs. 56%; p<0.0001); cirrhosis (70% vs. 59%; p=0.005); and hepatocellular carcinoma (HCC; 8% vs. 3%; p=0.009). Over a 3 year median follow-up period, diabetics relative to nondiabetics had a higher probability to develop cirrhosis (60% vs. 41%; p=0.022) and HCC (27% vs. 10%; p=0.045). There was a trend for increased development of hepatic encephalopathy in diabetics compared to nondiabetics (55% vs. 39%; p=0.053), and there was no difference between the two groups in survival or other liver disease complications. Conclusions DM increased risk for cirrhosis and HCC among patients with ALD and NAFLD. Prospective studies with longer follow-up periods are needed to examine the impact of DM on survival and the role of aggressive HCC screening in diabetic cirrhotics.

[1]  R. Wiesner,et al.  Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease , 2013, Transplantation.

[2]  D. García-Compeán,et al.  The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. , 2011, Annals of hepatology.

[3]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[4]  P. Rosenthal,et al.  American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.

[5]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[6]  F. Marra,et al.  Adipokines in liver diseases , 2009, Hepatology.

[7]  Chien-Jen Chen,et al.  Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. , 2008, Gastroenterology.

[8]  M. Lai,et al.  Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection , 2006, Hepatology.

[9]  C. Tilquin,et al.  Risk Adjustment in Outcome Assessment: the Charlson Comorbidity Index , 1993, Methods of Information in Medicine.

[10]  I. Wanless,et al.  Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.

[11]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[12]  A. Alberti,et al.  Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. , 2008, World journal of gastroenterology.

[13]  C. Palmeira,et al.  Hyperglycemia decreases mitochondrial function: the regulatory role of mitochondrial biogenesis. , 2007, Toxicology and applied pharmacology.

[14]  A. Jenkins,et al.  Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. , 2005, Diabetes care.

[15]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[16]  Z. Younossi,et al.  Nonalcoholic fatty liver disease in patients with type 2 diabetes. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[18]  Manal M. Hassan,et al.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma , 2010, Cancer.

[19]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[20]  F. Folli,et al.  Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways , 1999, Hepatology.

[21]  T. Mizoue,et al.  Prospective study of diabetes mellitus and liver cancer in Japan , 2001, Diabetes/metabolism research and reviews.

[22]  J. Crespo,et al.  Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients , 2001 .

[23]  A. Facciorusso The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. , 2013, Current diabetes reviews.

[24]  V. de Lédinghen,et al.  Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. , 2006, Journal of hepatology.

[25]  W. Aronow Updated National Cholesterol Education Program III guidelines. , 2005, Journal of the American Medical Directors Association.

[26]  P. Hayes,et al.  Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.

[27]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.

[28]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[29]  H. Adami,et al.  Excess risk of primary liver cancer in patients with diabetes mellitus. , 1996, Journal of the National Cancer Institute.

[30]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[31]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[32]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[33]  C. Miranda,et al.  Alcohol and HCV Chronic Infection Are Risk Cofactors of Type 2 Diabetes Mellitus for Hepatocellular Carcinoma in Italy , 2010, International journal of environmental research and public health.

[34]  T. Saibara,et al.  Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients , 2014, Journal of Gastroenterology.

[35]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[36]  M Linet,et al.  Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.

[37]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[38]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[39]  H. Tilg,et al.  Adiponectin and its receptors in patients with chronic hepatitis C. , 2005, Journal of hepatology.

[40]  J. Bruix,et al.  Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma , 2010, European journal of gastroenterology & hepatology.

[41]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[42]  F. Davis,et al.  Re: Excess risk of primary liver cancer in patients with diabetes mellitus. , 1997, Journal of the National Cancer Institute.

[43]  A. Hashmi,et al.  Diabetes mellitus and decompensated cirrhosis: Risk of hepatic encephalopathy in different age groups (糖尿病与失代偿性肝硬化:不同年龄组的肝性脑病风险) , 2013, Journal of diabetes.

[44]  R O Morgan,et al.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.

[45]  N. Chalasani,et al.  Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .

[46]  Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. , 1994, Hepatology.

[47]  Henry Völzke,et al.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? , 2012, World journal of gastroenterology.

[48]  Lu-Yu Hwang,et al.  Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.

[49]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[50]  A. Iwama,et al.  Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells , 2013, PloS one.

[51]  Sara Rosenbaum,et al.  Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. , 2005, The American journal of cardiology.

[52]  P. Zimmet,et al.  Diagnosis and classification of diabetes mellitus , 2002 .

[53]  A. Singal,et al.  Recent trends in the epidemiology of alcoholic liver disease , 2013, Clinical liver disease.

[54]  Rohit Loomba,et al.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. , 2013, Journal of diabetes and its complications.